Diana Danca’s practice focuses on complex patent litigation with an emphasis in the chemical and pharmaceutical arts.
Prior to joining the firm, Dr. Danca spent several years as a medicinal chemist in the biotech/pharmaceutical industry. Her work focused on the discovery and synthesis of lead compounds in the cancer, metabolic and central nervous system therapeutic areas. She is also a co-inventor of NINLARO®, the first and only oral proteasome inhibitor used in the treatment of multiple myeloma in combination with other medication in people who have received at least one other prior treatment. Dr. Danca is also the co-inventor on several pharmaceutical patents and patent applications. She has published several articles in peer-reviewed journals in the field of synthetic organic chemistry and medicinal chemistry and has presented her research at national scientific meetings.